Ardea touts IIa data

San Diego-based Ardea BioSciences is reporting positive results from its Phase IIa proof-of-concept study for an experimental HIV therapy. "RDEA806's robust antiviral potency, combined with its excellent tolerability profile in over 130 healthy volunteers and HIV-infected patients treated in clinical studies to-date, make RDEA806 a promising candidate for further investigation as a first-line agent for the treatment of HIV," said Dr. Graeme Moyle, director of HIV research, Chelsea and Westminster Hospital. Ardea release